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Abstract We have recently reported that human fallopian
tubes, which are discarded during surgical procedures of
women submitted to sterilization or hysterectomies, are a
rich source of human fallopian tube mesenchymal stromal
cells (htMSCs). It has been previously shown that human
mesenchymal stromal cells may be useful in enhancing the
speed of bone regeneration. This prompted us to investigate
whether htMSCs might be useful for the treatment of
osteoporosis or other bone diseases, since they present a
pronounced capacity for osteogenic differentiation in vitro.
Based on this prior knowledge, our aim was to evaluate, in
vivo, the osteogenic capacity of htMSCs to regenerate bone
through an already described xenotransplantation model:
nonimmunosuppressed (NIS) rats with cranial defects.
htMSCs were obtained from five 30–50 years old healthy
women and characterized by flow cytometry and for their
multipotencialityinvitrocapacity(osteogenic,chondrogenic
and adipogenic differentiations). Two symmetric full-
thickness cranial defects on each parietal region of seven
NIS rats were performed. The left side (LS) of six animals
was covered with CellCeram (Scaffdex)—a bioabsorbable
ceramic composite scaffold that contains 60% hydroxyapa-
titeand40%β-tricalciumphosphate—only,andtherightside
(RS) with the CellCeram and htMSCs (10
6 cells/scaffold).
The animals were euthanized at 30, 60 and 90 days
postoperatively and cranial tissue samples were taken for
histological analysis. After 90 days we observed neobone
formation in both sides. However, in animals euthanized 30
and 60 days after the procedure, a mature bone was observed
only on the side with htMSCs. PCR and immunofluores-
cence analysis confirmed the presence of human DNA and
thus that human cells were not rejected, which further
supports the imunomodulatory property of htMSCs. In
conclusion, htMSCs can be used successfully to enhance
bone regeneration in vivo, opening a new field for future
treatments of osteoporosis and bone reconstruction.
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Introduction
Osteoporosis is a common skeletal condition, characterized
bya decreaseinbone’s density and increased riskoffractures.
Its prevalence is much higher in postmenopausal women than
in older men, and may affect about 40–70% of women over
70 years old. Although osteoporosis is still under-diagnosed
and under-treated, the risk of fracture is high and is associated
to morbidity, especially when it occurs in the spine and hip
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São Paulo, Brazil[1, 2]. Recent reports show that the use of mesenchymal
stromal cells (MSCs) isolated from adult organs and tissues
is becoming a very attractive strategy for the treatment of
fractures and other bone disorders such as congenital
anomalies, traumas and cancer [3–5].
Adult MSCs are typically defined as undifferentiated
multipotent cells endowed with the capacity for self-
renewal and the potential to differentiate into several
distinct cell lineages [6]. These progenitor cells, which
constitute a reservoir found within the connective tissue of
most organs, are involved in the maintenance and repair of
tissues throughout the postnatal life of an individual.
Functionally heterogeneous, MSCs populations isolated
from different tissues present a similar profile of cell
surface receptor expression. It is also well known that adult
stem cells are defined by their functional properties rather
than by marker expression. We and others have recently
shown that umbilical cord, dental pulp, orbicular oris
muscle, adipose tissue and fallopian tubes are a very rich
source of MSCs able to differentiate into muscle, cartilage,
bone and adipose cell lineages [7–11].
Bone is a tissue of constant remodeling and MSCs might
play an important role in this process, therefore contributing
to treat osteoporosis or other bone diseases. In addition, the
possibility to use autologous stem cells, from discarded
surgical tissues is of great interest. We have previously shown
that human fallopian tube mesenchymal stromal cells
(htMSCs) display great osteogenic differentiation in vitro
[11], but we have also observed that MSCs may differ in their
in vitro differentiation potential when injected in animal
models [12]. htMSCs could represent an additional autolo-
gous source of MSCs for bone repair for those women that
had their fallopian tube previously removed surgically, since
htMSCs are a cell population that can be rapidly expanded
for potential clinical applications [11]. Furthermore, their
pronounced capacity for osteogenic differentiation in vitro
prompted us to evaluate the osteogenic capacity of htMSCs to
regenerate bone in vivo. However, prior to start clinical trials,
it is of paramount importance to test whether it is possible to
make bone tissue engineering in vivo, using htMSCs.
Therefore, the aim of the present study was to evaluate, in
vivo, the osteogenic capacity of htMSCs to regenerate bone
when xenotransplanted to non-immunosuppressed (NIS) rats
with cranial defects, as already described before with MSCs
from different origins [8, 9].
Material and Methods
Human Fallopian Tube Collection and Processing
Human fallopian tubes (n=5) were obtained from hyster-
ectomy or tubal ligation/resection samples collected from
women aged 30–50 years who had not undergone exoge-
nous hormonal treatment for at least 3 months prior to
surgery. Furthermore, all donors were considered fertile,
since they had children by natural conception. Informed
consent was obtained from each patient and approval
granted from the ethics committee of the Biosciences
Institute of the University of São Paulo. All laboratory
experiments were carried out at the Human Genome
Research Center, São Paulo, Brazil.
All steps of collection and processing were previ-
ously described [11]. All samples that had been kept
frozen in liquid nitrogen were thawed and expanded
until the 4th passage, characterized by flow cytometry
and differentiation potential in vitro, before the in vivo
experiments.
Flow Cytometry Analysis
Flow cytometry analysis was performed using a Guava
EasyCyte microcapillary flow cytometer (Guava Technol-
ogies, Hayward, CA) utilizing laser excitation and
emission wavelengths of 488 and 532 nm, respectively.
Cells were pelleted, resuspended in PBS (Gibco—
Invitrogen, Carlsbad, CA) at a concentration of 1.0×10
5
cells/mL and stained with saturating concentration of
antibodies. After 45 min incubation in the dark at room
temperature, cells were washed three times with PBS
(Gibco, Invitrogen, Carlsbad, CA) and resuspended in
0.25 mL of cold PBS.
In order to analyze cell surface expression of protein
markers, adherent cells were treated with the following
anti-human primary antibodies: CD13-phycoerythrin [PE]
(Becton Dickinson, Franklin Lakes, NJ), CD29-PE-Cy5,
CD31-PE, CD34-PerCP, CD90-R-PE, human leukocyte
antigens (HLA)-ABC-FITC and HLA-DR-R-PE (Becton
Dickinson, Franklin Lakes, NJ), SSEA3 (Chemicon,
Temecula, CA), STRO1 (R&D Systems, Minneapolis,
MN), and SH3 and (kindly provided by Dr. Kerkis,
Butantan Institute, São Paulo, Brazil). Unconjugated
markers were reacted with anti-mouse PE secondary
antibody (Guava Technologies, Hayward, CA). Unstained
cells were gated on forward scatter to eliminate particulate
debris and clumped cells. A minimum of 5.000 events
were counted for each sample.
Mesenchymal Stromal Cells Differentiation
To evaluate the properties of mesenchymal stromal cells
differentiation, adherent cells (4th passages) underwent in
vitro adipogenic, chondrogenic and osteogenic differentia-
tions. Invitrogen Stem Pro differentiation medium kits
(A1007101, A1007001 and A1007201), prepared according
to manufacturer data sheets were used.
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Cells were kept in culture for 2 weeks. Confirmation of
adipogenic differentiation was obtained on day 21 by
intracellular accumulation of lipid-rich vacuoles stainable
with oil red O (Sigma-Aldrich, St. Louis, MO). For the oil
red O stain, cells were fixed with 4% paraformaldehyde
(PFA) for 30 min, washed, and stained with a working
solution of 0.16% oil red O for 20 min.
Chondrogenic
After 2 weeks of culture, monolayer cells were fixed with
4% PFA for 10 min and dyed with Toluidine Blue, which
stains extracellular matrix mucopolysaccharides. Staining
solution was prepared by adding 1% of Toluidine Blue
dissolved in distilled water containing 1% of sodium
borate, followed by filtering. Solution was added to each
culture well for 2 min and then washed with distilled water
and left to air-dry.
Osteogenic
Osteogenic differentiation was shown by formation of
calcium-hydroxyapatite-positive areas (von Kossa stain-
ing) on day 21. After two washes with PBS (Gibco—
Invitrogen, Carlsbad, CA) and one with distilled water, the
cells were incubated in 1% silver nitrate (Sigma- Aldrich,
St. Louis, MO) under ultraviolet light for 45 min. The
cells were then incubated in 3% sodium thiosulfate
(Sigma-Aldrich, St. Louis, MO) for 5 min. Counter-
staining was finally performed with Van Gieson stain.
The calcium accumulation was indicated by dark color.
Alizarin Red S staining, which is incorporated by
calcium-containing mineralized matrix, was also provided
for each cell line after 21 days of differentiation as well.
The methodology is described in the osteogenic kit data
sheet (A1007201/Invitrogen).
Animal Model
The present study was approved by the Animal Research
Ethics Committee at the Institute of Biosciences, University
of São Paulo. A total of seven NIS Wistar rats (3-month-old
males, body weight 320–420 g each) were selected. The
animals were anesthetized with intraperitoneal injections
(0.3 mL=100 g body weight) containing ketamine hydro-
chloride (5%) and xylazine (2%). The rats were then
positioned in a cephalostat during the procedure. A midline
skin incision from the nasofrontal area to the external
occipital protuberance was performed. The skin and
underlying tissues were reflected laterally to expose the
full extent of the calvaria. Two symmetrical full-thickness
cranial defects with 4.5 mm of diameter were made on
each parietal region using a micromotor drill under
constant irrigation with sterile physiologic solution to
prevent bone overheating. The duramater was maintained
intact. The left side (LS) of six animals was covered with
CellCeram scaffold (Scaffdex, ref CM0002) only—a
bioabsorbable ceramic composite scaffold that contains
60% hydroxyapatite and 40% β-tricalciumphosphate—
and the right side (RS) with the CellCeram and htMSCs
(10
6 cells/scaffold). In one control animal, the RS had
CellCeram only and nothing was added at the left side.
Scaffolds with htMSCs were prepared 24 h before the
surgeries. Firstly, cells were added on the surface of the
scaffold with 100 μl of culture medium (in a 35 mm cell
culture dish) and kept in culture for 1 h. After that, 2 ml of
medium was added and the scaffold with cells was kept in
culture overnight, until use. Animals were euthanized at
30, 60 and 90 days postoperatively and cranial tissue
samples were taken for histological analysis.
Electron Microscopy
Cells were fixed for 24 h at 4°C using the modified
Karnovsky solution, which contains 2.5% glutaraldehyde,
htMSCs Lineages T6 T7 T9 T10 T13
Marker Commitment/Relevance % Labeled cells
CD34 Hematopoietic SC factor 1.78 2.62 1.16 1.30 0.80
CD31 Endothelial 0.68 0.44 2.90 0.43 1.85
HLA-DR HLA 0.64 0.65 3.80 0.53 1.58
HLA-ABC HLA 95.55 95.55 96.89 97.66 99.15
CD90 MSC/adherent marker 99.26 99.42 98.87 99.76 98.85
STRO1 MSC marker 2.12 9.60 8.75 2.29 2.41
SSEA3 Embryonic stem cell 0.09 0.46 3.81 0.42 0.70
SH3 MSC marker 98.58 98.56 99.43 98.07 98.77
CD13 MSC marker 98.44 98.24 98.89 98.24 99.50
CD29 MSC/adherent marker 98.81 98.24 96.92 98.78 99.45
Table 1 Cytometry analysis
of htMSCs. Analyzed
markers, commitment and
expression (the percentage
of positive labeled cells).
(GuavaTechnologies,
Hayward, CA, http://www.
guavatechnologies.com)
Stem Cell Rev and Rep (2012) 8:355–362 357Fig. 1 Multilineage differentiation in vitro. Panel a: a Example of
undifferentiated htMSC line (T6). b, c, d, e and f Osteogenic
differentiation after 3 weeks of induction for each cell line (T6, T7,
T9, T10, T13 respectively)—Alizarin S Red staining. Panel b: Each
cell line is represented in a row (T6, T7, T9, T10 and T13). Column a
Chondrogenic differentiation—Toluidine Blue staining (50×). Column
b Adipogenic differentiation—Oil Red staining (400×). Columns c
and d Osteogenic differentiation after 2 (c) and 3 (d) weeks of
induction—Von Kossa staining (200× and 100×). Black scale bar:
500 μm; Red scale bar: 100 μm (Microscope Zeiss Axiovert 200)
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buffer. The specimens were post fixed in 2% osmium
tetroxide solution, rinsed in distilled water for 1 h at room
temperature. Then, the cells were dehydrated in an
increasing series of ethanol and cleaned in an ultrasonic
apparatus (Gerador DA 200, Thornton Inpec Eletronica SA,
São Paulo, SP, Brazil) for 1 h. The samples were mounted
on metal stubs and covered with gold in a sputter coater
apparatus (Balzers Union SCD-040, Liechtesnstein). The
specimens were examined in a scanning electron micro-
scope at 20.0 kV (Jeol 6460LV, Tokyo, Japan).
Histological Preparation
Hematoxylin and Eosin (HE)
Sections from the 30th, 60th and 90th postsurgery days
were obtained for histological assessment. Tissue samples
were fixed in 10% formalin solution for 24 h, decalcified in
5% formic acid for 48 h, and paraffin embedded. For
morphologicalstudy,5-mmsectionsstainedwithhematoxylin
and eosin (HE) were examined under an AxioVert 200
microscope (Axio Imager Z1, Carl Zeiss, Oberkochen,
Germany).
Human DNA Amplification
To assess the presence of human cells in the new bone
tissue from the left side (scaffold only) and right side
(scaffold with htMSCs) from a rat euthanized 90 days after
transplantation we performed DNA extraction through
QIAamp DNA Mini KIT (Qiagen, Venlo, The Netherlands).
After that, PCR reactions were performed with specific
human amelogenin gene primers [13].
Immunohistochemistry
The sections were deparaffinized with two 5-min washes in
xylene, hydrated in graded ethanol series and then rinsed in
distilled water. The samples were fixed for 20 min at room
temperature with 4% paraformaldehyde in PBS and washed
three times with 100 mM glycine in PBS. For antigen
retrieval, slides were incubated for 40 min in citrate buffer
and then cooled for 20 min at room temperature, rinsed in
phosphate buffered saline (PBS), and blocked for 1 h in
immunofluorescent blocking buffer (IBB-5% BSA, 10%
FBS, 1X PBS, and 0.1% Triton X-100). Samples were then
incubated for 1 h at room temperature with 1:100 mouse
anti-human nuclei monoclonal antibody (HuNu; Chemicon,
Temecula, CA), washed with PBST, and incubated with
secondary antibody (1:600 Alexa Fluor 456 anti-mouse
IgG; Invitrogen) for 1 h at room temperature. Slides were
examined using an Axiovert 200 microscope (Axio Imager
Z1, Carl Zeiss, Oberkochen, Germany).
Results
Flow Cytometry Analysis
The five lineages of htMSCs chosen for the experiments
did not express the hematopoietic lineage marker CD34 and
the endothelial marker CD31. In addition, the majority of
cells expressed high levels of adhesion markers (CD29 and
CD90) and MSCs markers (CD13, SH3 and SSEA3). Cells
were also positive for HLA-classI(HLA-ABC)butnegative
Fig. 2 Electron microscopy. Scaffold seeded with htMSC. a Entire
scaffold b Visual approach to identification of the cells (arrows) c
htMSC in detail, attached onto scaffold
Stem Cell Rev and Rep (2012) 8:355–362 359for HLA-class II (HLA-DR), as well for the presumed MSCs
marker Stro1 (Table 1).
Multilineage Differentiation
The plasticity of each chosen lineage of htMSCs was
assessed 2 weeks after mesodermal induction for adipo-
genic and chondrogenic differentiation. In order to confirm
the good osteogenic capacity of each chosen htMSCs line,
osteogenic differentiation was assessed 2 and/or 3 weeks
after mesodermal induction. The htMSCs differentiated in
adipogenic, chondrogenic, and osteogenic tissues in vitro
(Fig. 1), confirming their mesenchymal nature and their
multipotent potential.
Electron Microscopy
Electron microscopy analysis confirmed the attachment of
htMSCs onto the scaffolds (Fig. 2).
Histological Analysis
In Vivo Osteogenic Potential of htMSCs
We have evaluated the in vivo osteogenic potential of
htMSCs using a previously established model [8, 9]. None
of the animals died of infection or any other complication
as a result of surgery or cell transplantation process.
Histological examination of the cranial defect 30 days
postsurgery in two animals revealed intense deposition of
new bone on the right side, with CellCeram and 10
6
htMSCs (Fig. 3b and b′). On the other hand, the side
containing only CellCeram had the defect filled with loose
connective tissue exhibiting chronic inflammatory infiltrate,
intermingledwithremnantsofthescaffold(Fig.3a and a′). At
60 days postsurgery, a histological evaluation of the right
side, which contained both the htMSCs and the CellCeram,
revealed reduction of granulation tissue, and the bone was in
an advanced maturation stage, with some lamellae formation
Fig. 3 In vivo osteogenic potential of htMSCs. a and b 30 days
postsurgery; a represents the left side, without stem cells on the
scaffolds, were neobone formation was not observed; b represents the
right side, with htMSCs, where it’s possible to perceive an intense
deposition of new bone. a′ and b′ The same histological slides in
higher magnification. c and d 60 days postsurgery; c represents the
left side, without stem cells on the scaffolds, were neobone
formation was not observed, but there was reabsorption of the
biomaterial; d represents the right side, with htMSCs, where there is
bone in an advanced maturation stage. c′ and d′ The same
histological slides in higher magnification. e and f 90 days
postsurgery; e represents the left side, without stem cells on the
scaffolds, where it is possible to see neobone formation onto the
reabsorbed scaffold local; f represents the right side, with htMSCS,
where it is possible to see a larger amount of neobone. e′ and f′ The
same histological slides in higher magnification. g Control animal,
with cranial defect, 90 days postsurgery. g′ The same histological
slide in higher magnification
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with CellCeram only, no neobone formation was observed
and there was a complete reabsorption of the scaffold
(Fig. 3c and c′). At 90 days postsurgery, we observed
neobone formation in both sides, but the right side presented
visually a larger amount of neobone (Fig. 3e, e′—left side,
Fig. 3f and f′—right side). One control animal, with the
cranial defect (without scaffold and/or stem cells) was kept
for 90 days. In this animal there was no spontaneous
skull regeneration of the cranial defect up to 12 weeks
(Fig. 3g and g′) as illustrated by histological analysis.
In the experimental group, a positive staining for human
nuclei through immunohistochemical analysis was observed
only on the right side of two animals 90 days postsurgery.
Besides that, human DNA was successfully amplified only in
samples extracted from the right side, where the htMSCs had
been transplanted (Fig. 4). Thus, these results confirmed that
the human cells are part of the new formed bone in the cranial
defect.
Discussion
Strategies for closing bone defects rely on the use of
autogenous cancellous bone grafts since they are immuno-
logically inert and potential suppliers of cells with
osteoconductive and osteoinductive properties which are
required for the bone healing process [14, 15]. However,
grafts may result in complications such as donor area
morbidity and post-surgical reabsortion [16, 17].
The possibility of using stem cells for bone regenerative
medicine has opened a new field of investigation. The
identification of sources for obtaining multipotent stem cells,
in particular through non-invasive procedures, is of utmost
interest. In this context, the human fallopian tubes that are
regularly discarded during hysterectomy or tubal ligation/
resection procedures may represent a good source of MSCs.
Here we report, for the first time, that htMSCs along with
CellCeram, present high osteogenic potential, for reconstruct-
ing a cranial defect in NIS male Wistar rats. The high
expression of mesenchymal and adhesion markers and the lack
of expression of hematopoietic or endothelial markers observed
in htMSCs lineages are similar to the ones seen in primary
MSCs obtained from other sources such as dental pulp,
orbicularis oris muscle, adipose or umbilical cord tissue [7–10].
Different types of scaffolds have been used associated
with MSCs for bone tissue engineering, such as collagen
membrane, hydroxyapatite, hydroxyapatite associated with
tricalcium phosphate, and others [8, 9, 18, 19]. We chose to
associate the htMSCs with CellCeram biomaterial as a
scaffold since it was designed to synthetically replicate the
hard calcium phosphate extracellular matrix of the bone and
display good porosity for cell infiltration and adhesion,
which may increase bone regeneration efficiency and
promote the rehabilitation of different types of bone defects.
We observed that htMSCs are able to reconstitute a cranial
defect in NIS male Wistar rats along with the CellCeram. The
newly formed bone tissue in animals analysed 90 days
postsurgery is, in part, of human origin, since we were able to
amplify its DNA using primers specific for the human
amelogenin gene. Additionally, positive staining for human
nuclei was exclusively obtained on the right side of the cranial
defect.
Although both human and rat cells can form bone, as
observed in 90 days postsurgery animals, the contribution of
human stem cells was essential because the scaffold alone was
not enough to close the cranial defect at least up to 60 days.
Fig. 4 Human DNA identification. 1 Immunohistochemistry for
detection of human nuclei. a, b and c represent the left side (without
human stem cells) with DAPI staining (in blue), human nuclei staining
(in red) and the overlapping of both pictures, respectively. a′,b ′ and c′
represent the right side (with human stem cells) with DAPI staining (in
blue), human nuclei staining (in red) and the overlapping of both
pictures, respectively. 2 Human DNA amplification, where: L represents
the DNA leader; LS represents the left side of the animal, without
human DNA detection; RS represents the right side of the animal with
human DNA; hF human female DNA; hM human male DNA
Stem Cell Rev and Rep (2012) 8:355–362 361In accordance with our and other researchers previous
reports [8, 9, 20], the present research reinforces that human
MSCs transplanted into nonimmunosupressed rats are not
rejected and do not elicit any immunological response. The
fact that they display the same immunomodulatory proper-
ties reported for MSC obtained from different sources
enhance the potential application of heterologous htMSCs
for bone regeneration [21, 22].
Moreover we show that the potential of htMSCs to
enhance bone regeneration is comparable to the previously
reported with dental pulp and orbicularis oris muscle MSCs
[8, 9], confirming that fallopian tubes MSCs combined with
biomaterials could be a promising additional source for
patients with bone diseases or defects.
Finally,althoughweobservedboneformationonbothsides
of the rat’s skull after 90 days, the contribution of human stem
cells enhanced significantly the recovery time of the injury.
In short, we demonstrated that htMSCs present excellent
osteogenic potential, both in vitro and in vivo. We show, for
the first time, that the autologous or heterologous use of
htMSCs can successfully enhance bone regeneration in
vivo, with potential use for treatment of osteoporosis and
bone reconstruction or regeneration.
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